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The article entitled “Model Criteria for Regulation
of Cord Blood Banks and Cord Blood Banking”
[1] is a concise set of recommendations for
the field of hematopoietic cell transplanta-
tion (HCT). Specifically, it relates to the field
of cord blood (CB) transplantation. It was put
together by members of the Government and
Global Affairs Committee of the Cord Blood
Association (CBA), who represent 15 different
countries, and was adopted by the Board of
Directors of the CBA on January 29, 2019. This
is a long-overdue set of guidelines for the inter-
national and national communities and offers
criteria for quality management, consent and
contract with the family for private banking,
donor screening and testing, collection proce-
dures for CB units, manufacturing effects, potency
of units and release of the CB units for transplan-
tation, shipping and transplantation, monitoring
of outcomes, registry participation and the shar-
ing of data, and laboratory testing. These are
noteworthy guidelines that help clarify present
needs. The guidelines will likely be modified in
time, as this model is adopted and other criteria
for use of this life-saving procedure are used
throughout the world. It is not a surprise that
these model guidelines have been provided by an
international group of investigators. While the
biology and science of CB hematopoietic stem
(HSC) and progenitor (HPC) cells that led to the
first and subsequent CB HCTs was a national
effort [2], the actual clinical use of these CB units
for CB HCT was an international affair [3] that has
been followed by well over 40,000 CB transplants
that have been used to treat a large variety of
malignant and non-malignant disorders that were
previously treated by bone marrow (BM) HCT
and that are now are being treated also by CB,
BM, and cytokine-induced mobilized peripheral
blood (mPB) HCT.
CB HCT has advantages and disadvantages
as a source of donor cells, compared with BM-
and mPB-HCT, which have been highlighted in
numerous review articles, including those on
behalf of my institution [4–6]. At this point in
time, it is crucial for the field of CB HCT to not
only set international guidelines for the use of
CB HSC and HPC for HCT, but to move forward
with enhancing the efficacy of CB HSC and HPC
for more favorable results. This encompasses
consistently using single CB units for transplan-
tation and substantially decreasing the time to
neutrophil, platelet, and immune cell recovery,
which is presently substantially slower than
that for BM, and especially for mPB HCT even
with very much improved clinical care of patients
undergoing CB HCT [6]. Efforts in these directions
include the collection of increased numbers of
HSC for banked CB units, the expansion of CB
HSC ex-vivo, and enhancing the homing effi-
ciency of the CB HSC so that they efficiently
reach the host BM microenvironment where
they can be nurtured for survival, proliferation,
self-renewal, and appropriate differentiation. All
these efforts are ongoing by many groups nation-
ally and internationally and have been noted in
several of review articles [4–6]. However, a
major concern for clinical improvements in the
field of CB HCT, which needs serious addres-
sing, is that most of these efforts have not yet
been adapted for clinical trials to test their effi-
cacy of action. It is imperative that a way be
found, and soon, to bring many of these inter-
esting procedures for testing in a clinical situa-
tion; some may be useful, while others may
not translate efficiently for clinical advantage.
These procedures need to be readily adaptable
for CB HCT, which means that the simpler the
procedure, the better. They must also be cost
effective, without addition of very high addi-
tional costs, unless the additional costs can be
justified in terms of short- and long-term clini-
cal effectiveness [7].
Preclinical and clinical efforts by my group,
with regard to experimental strategies to improve
clinical CB HCT, are diagrammed in Figure 1. This
includes the collection of increasing numbers of
HSC in CB units through the collection and pro-
cessing of the cells in a hypoxic atmosphere of
3% O2, while the cells are never subjected to
ambient air (21% O2) [8]. While this procedure
routinely allows collection of two- to fivefold
more phenotypically and functionally (engraft-
ing) HSC than that seen with the routine collec-
tion of such cells in ambient air, it is clearly
not feasible to adapt such collection/processing
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methods for routine use. Hence efforts are being investigated
to collect CB in ambient air but in the presence of cyclosporine
A or combinations of antioxidant(s) plus/minus epigenetic enzyme
inhibitor(s), which mimic to a degree the collection/processing
of cells in hypoxia [8, 9]. There is also a means to increase
numbers of already collected CB HSCs by expansion. In this
context, we have looked at adding either inhibitors of dipepti-
dylpeptidase (DPP)4 [10, 11], enhancing expression of Oct4
[12], using antagonists of peroxisome proliferator-activated
receptor (PPAR-γ) [13], or adding the heterochromatin remo-
deling nuclear protein DEK [14]. DEK acts in this effect through
a cytokine-mediated CXCR2 chemokine receptor-signaling path-
way, rather than through the remodeling of nuclear heterochro-
matin [14]. Ongoing efforts in this also include modulating CD166
expression [J. Zhang, C. Zhang, X. Huang et al., manuscript sub-
mitted for publication]. We have also investigated agents to en-
hance the homing capabilities of CB HSC. This includes the roles
of glucocorticosteroids [15], inhibitors of histone deacetylase
(HDAC) 5 [16], inhibitors of DPP4 in vitro [10, 11] and in vivo in
patients using the FDA-approved orally active DPP4-inhibitor sita-
gliptin [17], combinations of a DPP4 inhibitor plus prostaglandin
(PG)E [18], and short-term exposure of cells to mild heat (39C)
exposure [19]. Treatment of recipients undergoing CB HCT has
also used hyperbaric chambers [20]. All of the above-described
laboratory/clinical procedures, as well as those noted in my
reviews [4–6], can be used alone to enhance preclinical/clinical
CB HCT of human cells, but there is no reason that they cannot
also be used in combination in sequence as noted in Figure 1,
efforts currently ongoing in the laboratory, to see if such sequen-
tial combinations can more effectively enhance the efficacy of
the CB cells for HCT than each single procedure. Regardless of
the preclinical outcomes, it is crucial that a way be found to
investigate these efforts for clinical translation. This is not an easy
undertaking, because there are just so many transplant centers
doing CB HCT, and most centers have their favorite efforts, which
leaves little time or desire to pursue other areas. This will likely
require international CB HCT collaborative efforts, such as that
which helped start the field of CB HCT [3].
These additional efforts, if successful in a clinical setting,
will no doubt require additional modifications to the suggested
model criteria [1]. All in the field of lab-based scientific and
clinical efforts for enhanced CB HCT look forward to these
Figure 1. Recent strategies from the author’s laboratory to improve cord blood (CB) hematopoietic cell transplantation. This includes
isolating more HSCs through collection and processing of the cord blood in hypoxia (3% O2), or in ambient air with cyclosporine A or with
combinations of antioxidant(s) plus/minus epigenetic enzyme inhibitor(s), the ex vivo expansion of these cells by modulating DPP4, Oct4,
PPAR-γ, or DEK in the context of stem cell factor, thrombopoietin, and Flt3-ligand, enhancing the homing efficiency of HSCs with short-
term pretreatment of CB with glucocorticoids, inhibition of HDAC5, inhibition of DPP4, and PGE, along with inhibition of DPP4, exposure
of CB cells to mild hyperthermia, or the in vivo treatment of recipients with sitagliptin, an orally active DPP4 inhibitor, or by subjection of
the recipients to hyperbaric chamber exposure to reduce levels of erythropoietin. The references for each of the related publications are
noted in brackets. The red arrows suggest possibilities for sequencing these procedures for possible enhanced CB engraftment. Abbrevia-
tions: DPP, dipeptidylpeptidase; EPO, erythropoietin; FDA, U.S. Food and Drug Administration; FL, Flt3-ligand; HDAC, histone deacetylase;
HSC, hematopoietic stem cells; PG, prostaglandin; PPAR-γ, peroxisome proliferator-activated receptor-γ; SCT, stem cell factor; TPO,
thrombopoietin.
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clinical translations of ongoing lab and preclinical work and
will gladly welcome further modifications to the present pro-
posed guidelines, as necessary.
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